News Channels

20 Jan 2022 Elpiscience Announces First Patient Dosed in US Phase I Clinical Trial of Anti-CD39 Monoclonal Antibody ES002 for Treatment of Advanced Solid Tumors
19 Jan 2022 ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
19 Jan 2022 Altos Labs launches with the goal to transform medicine through cellular rejuvenation programming
19 Jan 2022 FDA Accepts for Review Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy for First-line Treatment of Advanced NSCLC
19 Jan 2022 CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients
19 Jan 2022 Seagen Reports Data From SEA-CD40 in Combination With Other Therapies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI)
19 Jan 2022 Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to Become Publicly Traded via Business Combination with Social Capital Suvretta Holdings Corp. III
19 Jan 2022 Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis
19 Jan 2022 Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib
19 Jan 2022 Imfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tract cancer
19 Jan 2022 Imfinzi plus tremelimumab demonstrated unprecedented survival in 1st-line unresectable liver cancer with 31% of patients alive at three years
19 Jan 2022 First subject enrolled in phase II/III study of Eisai's anti-MTBR tau antibody E2814 for dominantly inherited Alzheimer's disease (DIAD), conducted by DIAN-TU
19 Jan 2022 UCB to acquire Zogenix
18 Jan 2022 23andMe Announces Extension of GSK Collaboration and Update on Joint Immuno-oncology Program
18 Jan 2022 Akeso's AK117 (CD47 monoclonal antibody) in Combination with AK112 (PD-1/VEGF bi-specific antibody) to Initiate a Phase Ib/II Clinical Trial with or without Chemotherapy for the Treatment of Advanced Malignant Tumors
18 Jan 2022 ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan
18 Jan 2022 Amagma Therapeutics Announces Strategic Partnership with Innovent Biologics in Inflammatory Diseases
18 Jan 2022 City of Hope and CytoImmune announce study demonstrating novel off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cell-based therapy against pancreatic cancer
18 Jan 2022 Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors
18 Jan 2022 Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up